Global Hormone Replacement Therapy Market Size study & Forecast, by Product (Estrogen & Progesterone Replacement Therapy, Human Growth Hormone (HGH) Replacement Therapy, Thyroid Hormone Replacement Therapy, Testosterone Replacement Therapy, Parathyroid Ho

Global Hormone Replacement Therapy Market Size study & Forecast, by Product (Estrogen & Progesterone Replacement Therapy, Human Growth Hormone (HGH) Replacement Therapy, Thyroid Hormone Replacement Therapy, Testosterone Replacement Therapy, Parathyroid Hormone Replacement), by Route of Administration (Oral, Parenteral, Transdermal, Others), by Disease Type (Menopause, Hypothyroidism, Male hypogonadism, Growth hormone deficiency, Hypoparathyroidism) and Regional Analysis, 2023-2030

Global Hormone Replacement Therapy Market is valued at approximately USD 21.28 billion in 2022 and is anticipated to grow with a healthy growth rate of more than 6.6% over the forecast period 2023-2030. Hormone Replacement Therapy (HRT) is a medical treatment that involves supplementing or replacing hormones in the body to manage or alleviate symptoms associated with hormonal imbalances or deficiencies. It is commonly used to address symptoms related to menopause in women, but it can also be prescribed for other conditions. The Hormone Replacement Therapy Market is expanding because of factors such as the rising prevalence of hormonal disorders and increasing number of patients undergoing hormone replacement therapy and technological developments in drug delivery systems.

The market for hormone replacement treatment (HRT) is expanding as a result of factors including the prevalence of target diseases increasing The American Thyroid Association estimates that 12.0% of Americans would l experience thyroid disease at some point in their lives. Additionally, it stated that about 20.0 million Americans suffer from thyroid disease in year 2021. Furthermore, The National Institutes of Health (NIH) report 2020, revealed that nearly half of all post-menopausal women in the US have used HRT at least once. In addition, the report also states that 1.3 million American women are estimated to reach the menopause period each year in the country. Thus, the rising prevalence of various hormonal disorders is fostering market growth. In addition, increasing R&D investments and rising awareness about hormone deficiency is creating a lucrative opportunity for the market. However, the high cost of Hormone Replacement Therapy stifles market growth throughout the forecast period of 2023-2030.

The key regions considered for the Global Hormone Replacement Therapy Market study includes Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. North America dominated the market in 2022 owing to the dominance of branded products and the region's increasing disease prevalence. Asia Pacific is expected to grow significantly during the forecast period, owing to factors such as rising target populations, an increase in the number of collaborations for product development, geographic expansion of key players, and active participation of government and nonprofit organizations in the market space.

Major market player included in this report are:
Eli Lilly and Company
Bayer AG
Noven Pharmaceuticals, Inc.
Pfizer Inc.
Merck & Co., Inc.
Viatris, Inc.
Novo Nordisk A/S
F. Hoffmann-La Roche Ltd.
ASCEND Therapeutics US, LLC.
AbbVie, Inc.

Recent Developments in the Market:
In November 2022, I-MAB Biopharma Co., Ltd., and Jumpcan Pharmaceutical Group partnered to produce and market eftansomatropin alfa (TJ101) in China. The long-acting recombinant human growth hormone TJ101, which is presently undergoing a phase 3 clinical trial, is being used to treat paediatric growth hormone deficiency.

In February 2023, Korea’s Ministry of Food and Drug Safety announced the approval of Pfizer’s NGENLA for the treatment of hormone deficiency.

Global Hormone Replacement Therapy Market Report Scope:
Historical Data – 2020 - 2021
Base Year for Estimation – 2022
Forecast period - 2023-2030
Report Coverage - Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
Segments Covered - Product, Route of Administration, Disease Type, Region
Regional Scope - North America; Europe; Asia Pacific; Latin America; Middle East & Africa

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players.

The detailed segments and sub-segment of the market are explained below:

By Product:
Estrogen & Progesterone Replacement Therapy
Human Growth Hormone (HGH) Replacement Therapy
Thyroid Hormone Replacement Therapy
Testosterone Replacement Therapy
Parathyroid Hormone Replacement

By Route of Administration Type:
Oral
Parenteral
Transdermal
Others

By Disease Type:
Menopause
Hypothyroidism
Male hypogonadism
Growth hormone deficiency
Hypoparathyroidism

By Region:

North America
U.S.
Canada

Europe
UK
Germany
France
Spain
Italy
ROE

Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC

Latin America
Brazil
Mexico

Middle East & Africa
Saudi Arabia
South Africa
Rest of Middle East & Africa

Companies Mentioned
Eli Lilly and Company
Bayer AG
Noven Pharmaceuticals, Inc.
Pfizer Inc.
Merck & Co., Inc.
Viatris, Inc.
Novo Nordisk A/S
F. Hoffmann-La Roche Ltd.
ASCEND Therapeutics US, LLC.
AbbVie, Inc.

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.